Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices 91757 

ACF is currently working on future 

revisions to this information collection, 

which will be submitted to OMB for 

review and approval in 2025. Notices 

inviting public comment on those 

revisions will accompany that request, 

but comments received in response to 

this notice could also inform those 

revisions. Through this request process 

minor discrepancies were noted 

between the OMB-approved instruments 

and those currently in use. These minor 

errors were fixed in the versions 

included with the request to OMB. 

Respondents: General Departmental 

(GDSRAE), State (SSRAE), and 

Competitive (CSRAE) grant recipients, 

their subrecipients, and program 

participants. 

ANNUAL BURDEN ESTIMATES

Instrument 

Number of 

respondents 

(total over 

request 

period) 

Number of 

responses 

per 

respondent 

(total over 

request 

period) 

Avg. burden 

per response 

(in hours) 

Total/ 

annual burden 

(in hours) 

(1) Participant Entry Survey 

GDSRAE participants ...................................................................................... 126,130 1 0.1333 16,813 

SSRAE participants ......................................................................................... 317,633 1 0.1333 42,340 

CSRAE participants ......................................................................................... 20,136 1 0.1333 2,684 

(2) Participant Exit Survey 

GDSRAE participants ...................................................................................... 100,904 1 0.1667 16,821 

SSRAE participants ......................................................................................... 254,106 1 0.1667 42,360 

CSRAE participants ......................................................................................... 16,109 1 0.1667 2,685 

(3) Performance reporting data entry form: grant recipients 

GDSRAE grant recipients ................................................................................ 119 2 16 3,808 

SSRAE grant recipients ................................................................................... 39 2 16 1,248 

CSRAE grant recipients ................................................................................... 34 2 16 1,088 

(4) Performance reporting data entry form: subrecipients 

GDSRAE subrecipients ................................................................................... 252 2 13 6,552 

SSRAE subrecipients ...................................................................................... 426 2 13 11,076 

CSRAE subrecipients ...................................................................................... 63 2 13 1,638 

Estimated Total Annual Burden 

Hours: 149,113. 

Authority: 42 U.S.C. 1310. 

Mary C. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2024–27053 Filed 11–19–24; 8:45 am] 

BILLING CODE 4184–83–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2024–P–4163] 

Determination That NOXAFIL 

(Posaconazole) Delayed-Release 

Tablets, 100 Grams Was Not 

Withdrawn From Sale for Reasons of 

Safety or Effectiveness; Correction 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; correction. 

SUMMARY: The Food and Drug 

Administration (FDA) is correcting a 

notice that appeared in the Federal 

Register on October 16, 2024. The 

document announced that NOXAFIL 

(posaconazole) delayed-release tablets, 

100 grams (g), was not withdrawn from 

sale for reasons of safety or 

effectiveness. The document incorrectly 

listed the dosage strength as 100 g. The 

correct strength is 100 milligrams (mg). 

This notice corrects that error. 

FOR FURTHER INFORMATION CONTACT: Awo 

Archampong-Gray, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 51, Rm. 6243, 

Silver Spring, MD 20993–0002, 301– 

796–0110, Awo.Archampong-Gray@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In FR Doc. 

2024–23811, published in the Federal 

Register of Wednesday, October 16, 

2024 (89 FR 83504), appearing on pages 

83504 and 83505, the following 

corrections are made: 

1. On page 83504, in the second 

column, the title of the document is 

corrected to read ‘‘Determination That 

NOXAFIL (Posaconazole) DelayedRelease Tablets, 100 Milligrams, Was 

Not Withdrawn From Sale for Reasons 

of Safety or Effectiveness.’’ 

2. On page 83504, in the third 

column, in the SUMMARY, in the first 

paragraph, ‘‘NOXAFIL (posaconazole) 

delayed-release tablets, 100 grams (g),’’ 

is corrected to read ‘‘NOXAFIL 

(posaconazole) delayed-release tablets, 

100 milligrams (mg),’’. 

3. On page 83505, in the first and 

second columns, all uses of ‘‘100 g’’ are 

corrected to read ‘‘100 mg’’. 

Dated: November 7, 2024. 

Kimberlee Trzeciak, 

Deputy Commissioner for Policy, Legislation, 

and International Affairs. 

[FR Doc. 2024–27082 Filed 11–19–24; 8:45 am] 

BILLING CODE 4164–01–P 


khammond on DSK9W7S144PROD with NOTICES